News and Events

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).

Archer sponsors Breast Cancer research platform

ArcherDX is partnering with Susan G. Komen Colorado and the University of Colorado Cancer Center to create a local event to connect community physicians, patients, and advocates with academic researchers and industry leaders. Our vision is to provide an educational forum to raise awareness about advances in breast cancer research, treatment, and testing.

Archer at Immunology 2017

Archer exhibits at the American Association of Immunologists Annual Meeting–Immunology 2017 in Washington, DC. At the largest annual gathering of immunologists worldwide, scientists discuss breakthroughs across the full spectrum of topics in the Immunology.

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017

Archer presents workshop at Biomarkers and Immuno-Oncology World Congress 2017

We'll be exhibiting at Cambridge Healthtech Institute’s Thirteenth Annual Biomarkers and Immuno-Oncology World Congress and will presenting a poster and a workshop featuring on B- and T-Cell Immune Repertoire Characterization by Anchored Multiplex PCR and Next-Generation Sequencing. This conference is dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines.

Archer at 106th Annual Meeting of Japanese Society of Pathology in Tokyo

We'll be co-attending with Illumina at the inaugural Japanese Society of Pathology in Tokyo. We'll be presenting five posters at this event and giving away corresponding poster flyers with the lead scientist contact info for later review. This gathering will strive to establish a focus on diagnosis that is based on an integrated understanding of disease through the use of high-sensitivity, high-volume analytical technologies like next-generation sequencers and embrace the ideal of giving something back to medicine and society as the goal of pathology.

Meet us at the Rocky Mountain Blood Cancer Conference

Archer is Denver on April 8th promoting awareness of NGS in blood cancer cancer research at the Rocky Mountain Blood Cancer Conference hosted by the Leukemia and Lymphoma Society. This a free educational conference for patients, survivors, caregivers and healthcare professionals.

ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration (CFDA).